Apnimed, Inc. (APMD) company profile
APMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026
$17.80+1.52 (+9.34%)
Close on Nov 17, 2026Market cap $85.47MP/E –Yield –
About Apnimed
Pharmaceutical Preparations, SIC 2834
Apnimed, Inc. is listed on Nasdaq under the ticker APMD, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Apnimed, Inc.
- Headquarters
- Cambridge, MA
- Address
- 39 John F. Kennedy Street, 4th Flr. 02138
- Phone
- (617) 500-8880
- Website
- apnimed.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- APMD
- Exchange
- Nasdaq
- IPO date
- Jul 31, 2026
- Shares outstanding
- 42M, Sep 4, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1745648
- CUSIP
- 03770Y107
- ISIN
- US03770Y1073
- FIGI
- BBG023ML25G9
- Share class FIGI
- BBG023ML26P7
- EIN
- 82-1910611
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kevin Robert Lind | Chief Executive Officer, Director | – |
| Michael B. Kelly | Chief Financial Officer | – |
| Dennis Patrick Molnar | President | 58,014 |
| Paul R. Fonteyne | Director | – |
| William A. Jones Jr | Director | – |
| Paul J. Sekhri | Director | 12,500 |
| Gary Sender | Director | – |
| Lawrence G. Miller | Director | 459,092 |
| Chris Dimitropoulos | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 31, 2026
- Offer price
- $16.00
- Securities offered
- 12,000,000
- Gross proceeds
- $192.00M
- Exchange
- Nasdaq
- First trading day
- Jul 31, 2026
- First-day close
- $25.00+56.3%
- Lock-up ends (est.)
- Jan 27, 2027
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 29, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?